Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 72.50
Bid: 60.00
Ask: 85.00
Change: -3.50 (-4.61%)
Spread: 25.00 (41.667%)
Open: 72.50
High: 72.50
Low: 72.50
Prev. Close: 76.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

26 Jul 2023 07:00

RNS Number : 1647H
Biome Technologies PLC
26 July 2023
 

 

26 July 2023

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Trading Update

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides an unaudited trading update for the quarter ended 30 June 2023. The Company's unaudited interim results for the six months ended 30 June 2023 ("2023 H1") are expected to be announced on 27 September 2023.

 

Group revenues for 2023 H1 were £3.6m (2022 H1: £2.4m) an increase of £1.2m or 47% on 2022 H1. This has been driven by continued robustness of demand in the Bioplastics division from existing and new customers in North America, both for flexible film and filtration mesh applications.

 

The Group's trading during 2023 Q2 continued in line with management expectations with revenue for 2023 Q2 £1.7m, 24% ahead of the same period last year (2022 Q2: £1.4m), although lower than 2023 Q1 (2023 Q1: £1.9m).

 

The Group had a cash balance as at 30 June 2023 of £0.93m (30 June 2022: £0.65m) and had 2026 convertible loan notes outstanding of £0.85m and no bank debt.

 

Bioplastics Division

 

The division's revenues for 2023 H1 were £3.0m, a 50% increase on 2022 H1 (2022 H1: £2m). 2023 Q2 revenues were £1.4m, 11% behind 2023 Q1 (2023 Q1: £1.6m) but 37% ahead of 2022 Q2 last year (2022 Q2: £1.0m).

 

The Bioplastics division continues to see a high level of interest in its products in North America across a wider variety of applications than has been seen traditionally. Management expects demand for the division's products in 2023 H2 to continue and reach similar levels to that experienced in the 2023 Q2, with further growth linked to product launches (the timing of which remain uncertain as referenced in previous trading statements).

 

RF Technologies Division

 

Revenues in the RF Technologies division for the 2023 Q2 were £0.3m, consistent with 2022 Q2 (£0.3m) and in line with 2023 Q1 (2023 Q1: £0.3m). Revenues for 2023 H1 were £0.5m representing an increase of 25% compared to 2022 H1 (2022 H1: £0.4m).

 

On 22 June 2023, the division announced a significant new contract win with a revenue value of £452,000 for the supply of a novel induction furnace system to a global manufacturer of scientific glass products. As highlighted in that announcement, specific revenue timing was dependent on the availability of key components that were to be identified during the design phase. Due to issues with the availability of certain of these components, it is now anticipated that all revenue associated with this contract will be recognised in 2024.

 

The division continues to be in discussions with a number of potential customers regarding contracts that would have revenue recognition potential for 2023 H2 and beyond.

 

Management is pleased with the novel market sectors in which the division is building a pipeline of new and potential new business and the scale of some of the opportunities in this pipeline. We remain cautious on the precise timing of revenue recognition, given much of this work requires considerable new collaborative design with customers and draws on components from supply chains that remain somewhat uncertain.

 

Group Outlook

 

The Board is pleased that both divisions are performing well. The Bioplastics division continues to outperform substantially against last year and, despite the expected timing delay in being able to recognise revenue for its newly won large contract, the RF Technologies division is confident of winning further business of a similar nature.

 

Whilst we continue to be cautious in light of the current macroeconomic environment and despite the changes in the sales mix between the divisions, management's outlook for the overall performance of Biome for 2023 remains unchanged and in-line with current market expectations.

 

-Ends-

 

For further information please contact:

Biome Technologies plc

Paul Mines, Chief Executive Officer

Rob Smith, Chief Financial Officer

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner/Tony Quirke (Sales and Corporate Broking)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics and RF Technologies.

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil- based polymers.

 

RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics and other industrial markets.

 

www.biometechnologiesplc.com www.biomebioplastics.com and www.thinkbioplastic.com www.stanelcorftechnologies.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKPBNABKDBOB
Date   Source Headline
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement
11th Apr 20057:00 amRNSRe Agreement
7th Apr 20057:00 amRNSRe Agreement
6th Apr 200512:41 pmRNSAdditional Listing
24th Mar 20057:00 amRNSRe Contract
22nd Mar 20054:49 pmRNSAnnual Report and Accounts
21st Mar 20057:02 amRNSStatement on High Court
1st Mar 20057:01 amRNSUpdate re. trials with Asda
28th Feb 20057:00 amRNSFinal Results
23rd Feb 20054:45 pmRNSAdditional Listing
9th Feb 20053:16 pmRNSAgreement and Placing
8th Feb 20057:00 amRNSUpdate re. trials with Asda
31st Jan 20059:09 amRNSRe. Agreement
25th Jan 20057:00 amRNSDirectorate Change
17th Jan 200511:44 amRNSAdditional Listing
4th Jan 200511:06 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.